摘要:
Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.
摘要:
A bubble manufacturing container 20 of the present invention includes: a container body 21 having an opening portion; and a rubber stopper 221 provided on the opening portion of the container body 21. The rubber stopper 221 is constituted so that the bubbles 1 of an inside of the container body 21 are able to be taken by piercing an injection needle. It is preferred that the bubble manufacturing container 20 has a fastening portion 222 provided on the rubber stopper 221, having an opening and sealing the container body 21 with the rubber stopper 221. Furthermore, it is preferred that the container body 21 mounts a weight portion.
摘要:
A method for manufacturing bubbles of the present invention includes: injecting an aqueous liquid 10 into a container 20 to a predetermined height; and vibrating the container at the number of revolution of equal to or higher than 5,000 rpm such that the aqueous liquid 10 repeatedly collides with an inner surface of the container 20. According to the manufacturing method, simply by vibrating the container 20 at a predetermined number of revolution, a large amount of bubbles 1 having a uniform size can be stably generated in the aqueous liquid 10. Furthermore, the vibrating the container 20 is preferably performed in a state where an internal pressure of the container 20 is higher than 1.0 atm.
摘要:
Modified or attenuated viruses and methods for preparing the modified viruses and modulating attenuation are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The viruses also can be used in diagnostic methods.
摘要:
Modified or attenuated viruses and methods for preparing the modified viruses and modulating attenuation are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The viruses also can be used in diagnostic methods.
摘要:
Disclosed herein are methods and devices for detection of bacterial HAI. Disclosed methods may be utilized for continuous in vivo monitoring of a potential bacterial infection site and may be utilized to alert patients and/or health care providers to the presence of pathogenic bacteria at an early stage of infection. Disclosed methods include utilization of recombinant bacteriophage to deliver to pathogenic bacteria a translatable genetic sequence encoding an optically detectable marker or an enzyme capable of producing an optically detectable marker. Upon detection of the optical signal produced by the marker, medical personnel may be alerted to the presence of pathogenic bacteria at the site of inquiry. Any bacterial causative agent of HAI may be detected according to disclosed methods.
摘要:
There is presently provided methods of monitoring retinopathy in a live transgenic, non-human animal, the methods comprising providing a live transgenic non-human animal having a retinal pathology or a pre-disposition for a retinal pathology, wherein a nucleic acid molecule encoding a fluorescent protein under control of a GFAP promoter is integrated into the genome of the transgenic non-human animal; and detecting in vivo in the retinal glia of the transgenic non-human anhnal fluorescence levels of the fluorescent protein.